Current Cancer Drug Targets
Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Contents
Current Cancer Drug Targets , Volume 17 - Number 1
Biography
Review Article
LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
, 17(1): 3 - 16Uzma Malik and Aneela Javed
DOI: 10.2174/156800961701161202200445
Review Article
Novel Strategies to Discover Effective Drug Targets in Metabolic and Immune Therapy for Glioblastoma
, 17(1): 17 - 39Gang Wang*, Xing-Li Fu, Jun-Jie Wang, Rui Guan and Xiang-Jun Tang
DOI: 10.2174/1568009616666160512145436
Review Article
OncomicroRNAs-Mediated Tumorigenesis: Implication in Cancer Diagnosis and Targeted Therapy
, 17(1): 40 - 47Nana Zheng, Ping Yang, Zhiwei Wang and Quansheng Zhou
DOI: 10.2174/1568009616666160216130608
Review Article
Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development
, 17(1): 48 - 52Alberto Ocana and Atanasio Pandiella
DOI: 10.2174/1568009616666151203224714
Review Article
UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target
, 17(1): 53 - 61Samantha Banford and David J. Timson
DOI: 10.2174/1568009616666160922102641
Research Article
Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?
, 17(1): 62 - 73Sofia Braga, Joana Cardoso, Saudade Andre, Margarida Brito, Pedro Sanchez, Lurdes Orvalho, Lucilia Salgado, Sergio Dias, Jose B. Pereira-Leal and Jose Luis Passos-Coelho
DOI: 10.2174/1568009616666161025114914
Research Article
Strong Anti-tumorous Potential of Nardostachys jatamansi Rhizome Extract on Glioblastoma and In Silico Analysis of its Molecular Drug Targets
, 17(1): 74 - 88Himanshi Kapoor, Nalini Yadav, Madhu Chopra, Sushil Chandra Mahapatra and Veena Agrawal
DOI: 10.2174/1570163813666161019143740
Research Article
EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo
, 17(1): 89 - 97Chenfei Zhou, Liangjun Zhu, Jun Ji, Fangmi Ding, Chao Wang, Qu Cai, Yingyan Yu, Zhenggang Zhu and Jun Zhang
DOI: 10.2174/1568009616666161013101657
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
Center for Drug Discovery
University of Houston
Houston, TX
Biography
Biography of Ruiwen Zhang
Ruiwen Zhang is the Robert L. Boblitt Endowed Professor in Drug Discovery and Director of the Drug Discovery Institute at the University of Houston. With over 30 years of experience in the field of biomedical research, particularly in the area of clinical pharmacology and therapeutics, pharmaceutical and toxicological research, Dr. Zhang’s research has been continuously funded by NIH and DoD, and other agencies. He has published more than 230 papers, 2 books, and more than 50 invited reviews/book chapters as well as more than 180 meeting abstracts. For his outstanding contributions in pharmaceutical sciences, Dr. Zhang was elected as a Fellow of American Association for the Advancement of Science (AAAS) in 2009. Dr. Zhang is recently elected as Fellow of National Academy of Inventors (2018).
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Post Publication Discussions and Corrections⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Short Guide⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Quick Links
Advertisement
Webmaster Contact: info@benthamscience.net